IWN ETF Implied Analyst Target Price: $198.15

The iShares Russell 2000 Value ETF (IWN) has a weighted average implied analyst target price of $198.15 per unit, suggesting 19.78% upside from its recent trading price of $165.43. Three of IWN's underlying holdings with notable upside are MaxCyte Inc (MXCT), Enanta Pharmaceuticals Inc (ENTA), and TriSalus Life Sciences Inc. (TLSI), with analyst target prices 212.50%, 144.25%, and 127.15% above their recent prices, respectively. Analysts' optimism may reflect future growth potential, but could also be a precursor to target price downgrades.

The iShares Russell 2000 Value ETF (IWN) has been gaining attention from analysts and investors alike, with a weighted average implied analyst target price of $198.15 per unit. This suggests a potential 19.78% upside from its recent trading price of $165.43. The ETF, which tracks the Russell 2000 Value Index, has shown strong performance in recent weeks, with gains of 7.99% since June 20, 2025 [1].

Analysts are particularly optimistic about three of IWN's underlying holdings: MaxCyte Inc (MXCT), Enanta Pharmaceuticals Inc (ENTA), and TriSalus Life Sciences Inc. (TLSI). The analyst target prices for these companies are 212.50%, 144.25%, and 127.15% above their recent prices, respectively. These target prices reflect the analysts' optimism about the future growth potential of these companies, which are all engaged in the biotechnology sector [2].

The iShares Russell 2000 Value ETF is expected to rise 14.93% during the next three months, with a 90% probability of holding a price between $182.09 and $192.40 at the end of this period. The ETF has shown strong short-term trends, with gains in 8 of the last 10 days and an increase of 4.91% over the past two weeks. The ETF is also supported by buy signals from short and long-term moving averages, as well as a Golden Star Signal in the long-term chart [1].

However, analysts caution that the absence of financial performance data for MaxCyte Inc in its upcoming Q2 2025 earnings release could signal financial uncertainty or issues that the company is not ready to disclose. Additionally, the requirement for investors to register online for the earnings call could limit participation and transparency for shareholders [2].

In conclusion, the iShares Russell 2000 Value ETF shows strong upside potential, with analysts optimistic about its future performance. However, investors should be aware of potential risks and uncertainties, such as the absence of financial performance data for one of its underlying holdings.

References:
[1] https://stockinvest.us/stock/IWN
[2] https://www.nasdaq.com/articles/maxcyte-inc-release-second-quarter-2025-financial-results-august-6th